Canetti, D;
Rendell, NB;
Gilbertson, JA;
Botcher, N;
Nocerino, P;
Blanco, A;
Di Vagno, L;
... Taylor, GW; + view all
(2020)
Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre.
Clinical Chemistry and Laboratory Medicine
, 58
(6)
pp. 948-957.
10.1515/cclm-2019-1007.
Preview |
Text
Canetti_10.1515_cclm-2019-1007.pdf - Published Version Download (421kB) | Preview |
Abstract
Systemic amyloidosis is a serious disease which is caused when normal circulating proteins misfold and aggregate extracellularly as insoluble fibrillary deposits throughout the body. This commonly results in cardiac, renal and neurological damage. The tissue target, progression and outcome of the disease depends on the type of protein forming the fibril deposit, and its correct identification is central to determining therapy. Proteomics is now used routinely in our centre to type amyloid; over the past 7 years we have examined over 2000 clinical samples. Proteomics results are linked directly to our patient database using a simple algorithm to automatically highlight the most likely amyloidogenic protein. Whilst the approach has proved very successful, we have encountered a number of challenges, including poor sample recovery, limited enzymatic digestion, the presence of multiple amyloidogenic proteins and the identification of pathogenic variants. Our proteomics procedures and approaches to resolving difficult issues are outlined.
Archive Staff Only
 |
View Item |
